

# Arne Ring

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4466239/publications.pdf>

Version: 2024-02-01

53  
papers

1,801  
citations

331259

21  
h-index

264894

42  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1933  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	5.5	245
2	Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 939-946.	2.2	163
3	Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 786-794.	2.2	161
4	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1171-1178.	1.0	124
5	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2013, 166, 983-989.e7.	1.2	116
6	Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. <i>Diabetic Medicine</i> , 2010, 27, 1409-1419.	1.2	110
7	Pharmacokinetics of linagliptin in subjects with hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 75-85.	1.1	63
8	Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. <i>Current Medical Research and Opinion</i> , 2009, 25, 1963-1972.	0.9	58
9	Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1055-1061.	1.0	54
10	A randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and feasibility study. <i>Trials</i> , 2015, 16, 531.	0.7	52
11	The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 542-550.	2.2	50
12	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2012, 3, 10.	1.2	46
13	Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg and 10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects. <i>Clinical Pharmacokinetics</i> , 2010, 49, 829-840.	1.6	45
14	Complete Versus Lesion-Only Primary PCI. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2713-2724.	1.2	43
15	Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2011, 36, 17-24.	0.6	39
16	The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. <i>Cardiovascular Diabetology</i> , 2013, 12, 70.	2.7	37
17	Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010, 48, 367-374.	0.3	36
18	Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 123-129.	1.1	34

#	ARTICLE	IF	CITATIONS
19	The DPP4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 39-50.	1.1	31
20	Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010, 48, 652-661.	0.3	27
21	Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults. <i>Clinical Drug Investigation</i> , 2011, 31, 643-653.	1.1	23
22	A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects. <i>Clinical Therapeutics</i> , 2011, 33, 1096-1103.	1.1	20
23	Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4300-4307.	1.4	19
24	Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 49, 300-310.	0.3	19
25	Evaluation of a tailored intervention to improve management of overweight and obesity in primary care: study protocol of a cluster randomised controlled trial. <i>Trials</i> , 2014, 15, 82.	0.7	16
26	Evaluation of a Self-Administered Oral Glucose Tolerance Test. <i>Diabetes Care</i> , 2013, 36, 1483-1488.	4.3	14
27	Sample size determination in bioequivalence studies using statistical assurance. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2369-2377.	1.1	14
28	Statistical models for heart rate correction of the QT interval. <i>Statistics in Medicine</i> , 2010, 29, 786-796.	0.8	11
29	Residuals and Outliers in Replicate Design Crossover Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 835-849.	0.4	11
30	A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio <sup>®</sup> ) in cardiac surgery: the REVAKI <sup>®</sup> study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 709-720.	1.1	11
31	Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation. <i>Pharmaceutical Statistics</i> , 2011, 10, 265-276.	0.7	10
32	Cluster randomised trial of a tailored intervention to improve the management of overweight and obesity in primary care in England. <i>Implementation Science</i> , 2015, 11, 77.	2.5	9
33	Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 18, 85.	1.6	9
34	Interpretation of General Measures of Distribution Kinetics in Terms of a Mammillary Compartmental Model. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 1491-1493.	1.6	8
35	Statistical Characterization of QT Prolongation. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 543-562.	0.4	8
36	Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 889-895.	0.3	8

#	ARTICLE	IF	CITATIONS
37	Delayed Effects in the Exposure-Response Analysis of Clinical QTc Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 387-400.	0.4	7
38	Statistical reporting of clinical pharmacology research. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1159-1162.	1.1	7
39	Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 333-342.	1.1	6
40	Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 537-48.	0.3	5
41	Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. <i>Pharmaceutical Research</i> , 2000, 17, 583-588.	1.7	4
42	Bioequivalence of Linagliptin 5â€‰mg Once Daily and 2.5â€‰mg Twice Daily: Pharmacokinetics and Pharmacodynamics in an Open-label Crossover Trial. <i>Drug Research</i> , 2014, 64, 269-275.	0.7	4
43	Indirect bioequivalence assessment using network meta-analyses. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 947-955.	0.8	4
44	Trial protocol for a randomised controlled trial of red cell washing for the attenuation of transfusion-associated organ injury in cardiac surgery: the REDWASH trial. <i>Open Heart</i> , 2016, 3, e000344.	0.9	4
45	Evaluation of the drugâ€‰drug interaction potential of treosulfan using a physiologicallyâ€‰based pharmacokinetic modelling approach. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1722-1734.	1.1	4
46	The potential of the estimands framework for clinical pharmacology trials: Some discussion points. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1240-1247.	1.1	3
47	Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 549-63.	0.3	3
48	How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 611-614.	1.1	2
49	Evaluation of Markov chains to describe movements on tiling. <i>Open Journal of Mathematical Sciences</i> , 2019, 3, 358-381.	0.7	2
50	Equivalence Tests in Subgroup Analyses. <i>ICSA Book Series in Statistics</i> , 2018, , 201-238.	0.0	1
51	Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. <i>Statistics in Medicine</i> , 2020, 39, 4551-4573.	0.8	1
52	Author response to letter from Snyder et al. regarding manuscript entitled "Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidaseâ€‰4 inhibitor, linagliptin" by Graefeâ€‰Mody et al.. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 671-672.	2.2	0
53	19â€‰...The randomised complete vs. lesion only primary PCI trial " cardiovascular MRI substudy (CVLPRIT-CMR). <i>Heart</i> , 2015, 101, A10-A11.	1.2	0